Advertisement

Zeitschrift für Rheumatologie

, Volume 77, Issue 6, pp 484–492 | Cite as

Was der Rheumatologe vom Dermatologen lernen kann – oder: Gute Freunde kann niemand trennen

Schnittpunkte der beiden Domänen
  • K. Schäkel
  • A. Schirra
Leitthema

Zusammenfassung

Hintergrund

Die Rheumatologie und die Dermatologie sind 2 medizinische Fachbereiche, die eng miteinander verflochten sind.

Ergebnisse

Direkte fachliche Schnittpunkte finden sich bei der Psoriasis, Psoriasisarthritis, den Kollagenosen und Vaskulitiden. Chronisch entzündliche Erkrankungen können häufig mit Hautmanifestationen assoziiert sein und bedürfen in der Regel einer speziellen dermatologischen Behandlung. Die Versorgung und Abklärung von kutanen unerwünschten Wirkungen der systemischen rheumatologischen Therapien stellt eine weitere Ebene der Zusammenarbeit dar.

Schlussfolgerungen

Die bereits an vielen Kliniken vorhandene enge inhaltliche Zusammenarbeit von Rheumatologen und Dermatologen bringt große Vorteile für unsere Patienten, besonders bei schwierigen Krankheitsverläufen. Darüber hinaus bietet sich hier eine wertvolle Möglichkeit, voneinander zu lernen. Die erfolgreiche Einrichtung von Entzündungszentren in einigen größeren Kliniken ist der Beleg für eine Entwicklung hin zu einer verstärkten fächerübergreifenden Behandlung unserer Patienten.

Schlüsselwörter

Entzündungszentren Autoimmunerkrankung Psoriasis Interdisziplinarität Arzneimittelreaktionen 

What the rheumatologist can learn from the dermatologist—or: nobody can separate good friends

Interfaces of both domains

Abstract

Background

Rheumatology and dermatology are two medical disciplines, which are closely interwoven with each other.

Results

Frequent direct areas of cooperation are with psoriasis, psoriatic arthritis, connective tissue diseases and vasculitis. As a whole, chronic inflammatory diseases are frequently associated with cutaneous manifestations and require a specialized dermatological treatment. The diagnosis and treatment of adverse cutaneous reactions to systemic rheumatological treatment creates an additional area requiring a collaborative effort.

Conclusion

The close cooperation between rheumatology and dermatology clinics, beeing established in many institutions, has many advantages for our patients, especially in those with a complex course of the disease. Furthermore, it presents a valuable opportunity to learn from each other. The successful establishment of inflammation centers in some larger hospitals is proof for the development of an intensified interdisciplinary treatment of patients.

Keywords

Inflammation centers Autoimmune diseases Psoriasis Interdisciplinarity Drug reactions 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

K. Schäkel und A. Schirra geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Für Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, über die Patienten zu identifizieren sind, liegt von ihnen und/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.

Literatur

  1. 1.
    Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361(5):496–509CrossRefPubMedGoogle Scholar
  2. 2.
    Mossner R, Wilsmann-Theis D, Oji V, Gkogkolou P, Lohr S, Schulz P et al (2017) The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol.  https://doi.org/10.1111/bjd.15867 PubMedCrossRefGoogle Scholar
  3. 3.
    Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F et al (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 69(5):729–735CrossRefPubMedGoogle Scholar
  4. 4.
    Eder L, Wu Y, Chandran V, Cook R, Gladman DD (2016) Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis 75(9):1680–1686CrossRefPubMedGoogle Scholar
  5. 5.
    Gilliam JN, Sontheimer RD (1981) Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 4(4):471–475CrossRefPubMedGoogle Scholar
  6. 6.
    Chang AY, Piette EW, Foering KP, Tenhave TR, Okawa J, Werth VP (2011) Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 147(11):1261–1267CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Englert HJ, Hawkes CH, Boey ML, Derue GJ, Loizou S, Harris EN et al (1984) Degos’ disease: association with anticardiolipin antibodies and the lupus anticoagulant. Br Med J (Clin Res Ed) 289(6445):576CrossRefGoogle Scholar
  8. 8.
    Kalashnikova LA, Korczyn AD, Shavit S, Rebrova O, Reshetnyak T, Chapman J (1999) Antibodies to prothrombin in patients with Sneddon’s syndrome. Neurology 53(1):223–225CrossRefPubMedGoogle Scholar
  9. 9.
    Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989–2003CrossRefPubMedGoogle Scholar
  10. 10.
    van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65(11):2737–2747CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O et al (2018) Practical suggestions on intravenous iloprost in Raynaud’s phenomenon and digital ulcer secondary to systemic sclerosis: systematic literature review and expert consensus. Semin Arthritis Rheum.  https://doi.org/10.1016/j.semarthrit.2018.03.019 PubMedCrossRefGoogle Scholar
  12. 12.
    Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E et al (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50(12):3985–3993CrossRefPubMedGoogle Scholar
  13. 13.
    Lundberg IE, de Visser M, Werth VP (2018) Classification of myositis. Nat Rev Rheumatol 14(5):269–278CrossRefPubMedGoogle Scholar
  14. 14.
    Huang YL, Chen YJ, Lin MW, Wu CY, Liu PC, Chen TJ et al (2009) Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study. Br J Dermatol 161(4):854–860CrossRefPubMedGoogle Scholar
  15. 15.
    Davatchi F (2012) Diagnosis/classification criteria for Behcet’s disease. Patholog Res Int.  https://doi.org/10.1155/2012/607921 PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Schack S, Weber M, Oelzner P, Mireskandari M, Antonov D, Stallmach A (2015) Morbus Behcet or inflammatory bowel disease—a diagnostic and therapeutic dilemma. Z Gastroenterol 53(10):1187–1192CrossRefPubMedGoogle Scholar
  17. 17.
    Tugal-Tutkun I, Onal S, Ozyazgan Y, Soylu M, Akman M (2014) Validity and agreement of uveitis experts in interpretation of ocular photographs for diagnosis of Behcet uveitis. Ocul Immunol Inflamm 22(6):461–468CrossRefPubMedGoogle Scholar
  18. 18.
    McCallum DI, Kinmont PD (1968) Dermatological manifestations of crohn’s disease. Br J Dermatol 80(1):1–8CrossRefPubMedGoogle Scholar
  19. 19.
    Keltz M, Lebwohl M, Bishop S (1992) Peristomal pyoderma gangrenosum. J Am Acad Dermatol 27(2 Pt 2):360–364CrossRefPubMedGoogle Scholar
  20. 20.
    Hubbard VG, Friedmann AC, Goldsmith P (2005) Systemic pyoderma gangrenosum responding to infliximab and adalimumab. Br J Dermatol 152(5):1059–1061CrossRefPubMedGoogle Scholar
  21. 21.
    Garcia-Porrua C, Gonzalez-Gay MA, Vazquez-Caruncho M, Lopez-Lazaro L, Lueiro M, Fernandez ML et al (2000) Erythema nodosum: etiologic and predictive factors in a defined population. Arthritis Rheum 43(3):584–592CrossRefPubMedGoogle Scholar
  22. 22.
    Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O (2017) Severe cutaneous adverse reactions to drugs. Lancet 390(10106):1996–2011CrossRefPubMedGoogle Scholar
  23. 23.
    Fardet L, Flahault A, Kettaneh A, Tiev KP, Genereau T, Toledano C et al (2007) Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol 157(1):142–148CrossRefPubMedGoogle Scholar
  24. 24.
    Knoll K, Anzengruber F, Cozzio A, French LE, Murer C, Navarini AA (2016) Mucocutaneous ulcerations and pancytopenia due to methotrexate overdose. Case Rep Dermatol 8(3):287–293CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Chen KE, Yang CC, Lee Y‑YJ, Sung JM (2014) Widespread skin necrosis due to methotrexate overdose in a patient with CKD. Kidney Int 85(3):716–717CrossRefPubMedGoogle Scholar
  26. 26.
    Kalogirou EM, Katsoulas N, Tosios KI, Lazaris AC, Sklavounou A (2017) Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event? J Clin Exp Dent 9(2):e325–e328PubMedPubMedCentralGoogle Scholar
  27. 27.
    Vallabhaneni S, Chiller TM (2016) Fungal infections and new biologic therapies. Curr Rheumatol Rep 18(5):29CrossRefPubMedGoogle Scholar
  28. 28.
    Brandt O, Bircher AJ (2017) Delayed-type hypersensitivity to oral and parenteral drugs. J Dtsch Dermatol Ges 15(11):1111–1132PubMedGoogle Scholar
  29. 29.
    Rajan TV (2003) The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation. Trends Immunol 24(7):376–379CrossRefPubMedGoogle Scholar
  30. 30.
    Pichler WJ, Naisbitt DJ, Park BK (2011) Immune pathomechanism of drug hypersensitivity reactions. J Allergy Clin Immunol 127(3 Suppl):S74–S81CrossRefPubMedGoogle Scholar
  31. 31.
    Kerbleski JF, Gottlieb AB (2009) Dermatological complications and safety of anti-TNF treatments. Gut 58(8):1033–1039CrossRefPubMedGoogle Scholar
  32. 32.
    Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H et al (2006) New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 65(3):405–407CrossRefPubMedGoogle Scholar
  33. 33.
    Ko JM, Gottlieb AB, Kerbleski JF (2009) Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 20(2):100–108CrossRefPubMedGoogle Scholar
  34. 34.
    Aringer M, Smolen JS (2008) The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther 10(1):202CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Peleva E, Exton LS, Kelley K, Kleyn CE, Mason KJ, Smith CH (2018) Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol 178(1):103–113CrossRefPubMedGoogle Scholar
  36. 36.
    Lange E, Blizzard L, Venn A, Francis H, Jones G (2016) Disease-modifying anti-rheumatic drugs and non-melanoma skin cancer in inflammatory arthritis patients: a retrospective cohort study. Rheumatology (Oxford) 55(9):1594–1600CrossRefGoogle Scholar
  37. 37.
    Hagen JW, Pugliano-Mauro MA (2018) Nonmelanoma skin cancer risk in patients with inflammatory bowel disease undergoing thiopurine therapy: a systematic review of the literature. Dermatol Surg 44(4):469–480CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.HautklinikUniversitätsklinikum HeidelbergHeidelbergDeutschland

Personalised recommendations